A ready-to-deploy utilization-management policy module for PBMs and health plans that uses the new noninferiority-without-superiority cardiovascular evidence to place the typically lower-priced dulaglutide first for members with type 2 diabetes and established heart disease, with defined exceptions for weight-priority patients.
The SWOT analysis reveals a high-value opportunity to leverage the SURPASS-CVOT non-inferiority data to drive immediate cost savings for payers. While the evidence-based approach is strong, the primary risk lies in physician pushback and the tension between cardiovascular stability and the high market demand for tirzepatide's superior weight loss.
Strengths4
Weaknesses3
Opportunities3
Threats3
Essential for evaluating the internal strength of the evidence-based 'wedge' against the external threat of pharmaceutical manufacturer lobbying. · Generated 2026-10-09 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated